Operational Fixes At Cipla But All Eyes On Generic Advair
Executive Summary
Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.
You may also be interested in...
Cipla Trims Staff At Indian Plant As It Eyes Costs
The rumor mill has it that Cipla has effected significant staff cuts at its Pithampur facility in India, as it keeps a sharp eye on costs and drives efficiencies at its manufacturing operations. But the company isn’t saying much except that it routinely conducts "performance-based reviews."
Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress
Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.
Cipla Revs Up In US, Newer Markets To Cushion Against Volatility
US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.